Allogeneic stem cell transplantation in children with leukemia using human leukocyte antigen-mismatched unrelated donors

Pediatric Transplantation
P SedlácekJ Starý

Abstract

Allogeneic HSCT is a curative treatment, when chemotherapy fails, for certain malignant diseases. In Europe, only 15% of the indicated children have an HLA-matched sibling available; in 65-70% of others, HLA allele-matched (9-10/10) UDs can be identified. For the rest, it is necessary to identify other alternative donors (HLA-mismatched family or unrelated cord blood). We present our data of HSCT using HLA partially allele-mismatched (7-8/10) UDs in 24 children with leukemia. Uniform GvHD prophylaxis was used (rATG, CsA and MTX). Acute GvHD grade II was diagnosed in 70.8% of the patients and grade III-IV in 12.5%. Overall incidence of chronic GvHD was 38.7% (extensive in 30%). The probability of EFS was 60.3% (95% CI 35.5-78.1) and OS was 74.9 (95% CI 49.1-88.9). No difference in survival between PBSC and BM recipients was observed. TRM at day + 100 was 4%, and overall was 12.5%. We conclude that used combination of drugs for GvHD prophylaxis is efficient even for patients transplanted with grafts from a HLA-mismatched UDs. It enables stable engraftment, good control of GvHD, full reconstitution of immunity, and is not connected with unacceptable transplant-related mortality.

References

Aug 1, 1980·The American Journal of Medicine·H M ShulmanE D Thomas
Dec 17, 1998·Journal of Clinical Microbiology·H KimuraT Morishima
Feb 24, 2000·Journal of Medical Virology·N TanakaT Morishima
Oct 5, 2001·Expert Opinion on Pharmacotherapy·D Simpson
Sep 10, 2002·Transplant Immunology·Jean-Marie TiercyEddy Roosnek
Nov 7, 2002·Bone Marrow Transplantation·P DugganUNKNOWN Alberta Blood and Bone Marrow Transplant Program
Nov 15, 2002·International Journal of Hematology·Shinichiro Okamoto
Feb 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jürgen FinkeHartmut Bertz
Feb 19, 2003·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Peter PriftakisTina Dalianis
Feb 27, 2003·Pediatric Transplantation·Paul A Carpenter, Jean E Sanders
Jun 9, 2004·Blood Reviews·Thomas KlingebielDietrich Niethammer
Nov 6, 2004·Blood Cells, Molecules & Diseases·Peter LangDietrich Niethammer
Mar 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Franco AversaMassimo F Martelli
Apr 1, 2005·Leukemia·A YoshimiUNKNOWN European Working Group of MDS in Childhood (EWOG-MDS)
Jul 26, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Donna A WallUNKNOWN COBLT Steering Committee
Aug 22, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Robertson ParkmanNancy A Kernan
Sep 21, 2006·British Journal of Haematology·Bimalangshu R Dey, Thomas R Spitzer
Jan 11, 2007·Bone Marrow Transplantation·M MianoUNKNOWN Paediatric Diseases Working Party of the European Group for Blood and Marrow Transplantation

❮ Previous
Next ❯

Citations

May 4, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Béatrice PédronGhislaine Sterkers
Nov 26, 2008·Bone Marrow Transplantation·J Nowak

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Roland MeiselDagmar Dilloo
Tissue Antigens
Effie PetersdorfInternational Histocompatibility Working Group in Hematopoietic Cell Transplantation
© 2021 Meta ULC. All rights reserved